Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Exscientia Ltd ADR (NQ: EXAI ) 5.320 +0.020 (+0.38%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 535,197 Open 5.310 Bid (Size) 5.250 (95) Ask (Size) 5.430 (1) Prev. Close 5.300 Today's Range 5.210 - 5.500 52wk Range 3.800 - 7.910 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why. Today 12:34 EDT Merging with a former rival will bolster its capabilities. Via The Motley Fool EXAI Stock Earnings: Exscientia Misses EPS, Misses Revenue for Q2 2024 August 15, 2024 EXAI stock results show that Exscientia missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. Via InvestorPlace Performance YTD -14.95% -14.95% 1 Month +3.50% +3.50% 3 Month +2.50% +2.50% 6 Month -16.48% -16.48% 1 Year -18.28% -18.28% More News Read More Exscientia Business Update for Second Quarter and First Half 2024 August 15, 2024 From Exscientia plc Via Business Wire AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD August 14, 2024 Via Talk Markets How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates August 14, 2024 Via FinancialNewsMedia Topics Artificial Intelligence Exposures Artificial Intelligence How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates August 14, 2024 From FN Media Group LLC Via GlobeNewswire Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia? August 11, 2024 Via The Motley Fool Topics Artificial Intelligence Exposures Artificial Intelligence AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals August 08, 2024 Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities August 08, 2024 From Recursion Pharmaceuticals, Inc. Via GlobeNewswire AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD July 30, 2024 Via Talk Markets AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD July 18, 2024 Via Talk Markets Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout July 18, 2024 From Exscientia plc Via Business Wire Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD July 14, 2024 Via Talk Markets Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery July 10, 2024 From Exscientia plc Via Business Wire 3 Small-Cap Stocks With Explosive 2X Growth Potential July 08, 2024 Via InvestorPlace Clinical-Stage BioTech Drug Stocks Declined 13% In June July 01, 2024 Via Talk Markets EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm June 25, 2024 From The Schall Law Firm Via Business Wire The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Exscientia p.l.c. (EXAI) June 24, 2024 From The Law Offices of Frank R. Cruz Via Business Wire EXAI FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – EXAI June 24, 2024 From The Rosen Law Firm PA Via GlobeNewswire EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm June 24, 2024 From The Schall Law Firm Via Business Wire Largest Clinical-Stage BioTech Drug Stocks Declined 6% June 22, 2024 Via Talk Markets EXSCIENTIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Exscientia plc. and Encourages Investors to Contact the Firm June 21, 2024 From Bragar Eagel & Squire Via GlobeNewswire INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Exscientia June 21, 2024 From Faruqi & Faruqi LLP Via GlobeNewswire Lowey Dannenberg Notifies Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm June 21, 2024 From Lowey Dannenberg, P.C. Via GlobeNewswire EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm June 21, 2024 From Schall Law Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
